Jose Luis Turabian*
Citation: Turabian JL. Adverse Covid-19 Vaccines Booster Reactions Case Series, From November 2021 TO September 2022, In a General Medicine Office in Toledo, Spain. Medp Public Health Epidemiol. 2022; 1(1): mpphe–202210001.
Abstract
Background: There is lack of clinical outcome data on the safety of covid-19 vaccines
booster.
Objective: To study, in general medicine, clinical-epidemiological characteristics of patients
who consulted for self-reported adverse reactions to covid-19 vaccines booster.
Methodology: An observational, longitudinal and prospective case series study of patients
with adverse reactions to covid-19 vaccines booster, based on a cohort of patients in a family
medicine office in Toledo (Spain) was carried out from November 1, 2021 to September 1,
2022.
Results: Twenty-one cases of adverse reactions to covid-19 vaccines booster were included.
The mean age of the patients was 45 years. 67% were women. According to the criteria of
causality, 42% were probable. According to the time of appearance, the majority (76%) occurred
between 1-72 hours after shot. 52% were moderate (with interference with normal activities);
there was no severe adverse reaction. 81% of adverse reactions to covid-19 vaccines booster
occurred with Moderna mRNA-1273. Only 1 case had also presented an adverse reaction with
a previous dose of the vaccine. 71% had chronic diseases, being 21% from the genitourinary
group and 17% mental. 64% of the symptoms were from the group of symptoms, signs not
elsewhere classified (Injection site pain, throat pain, fever, chills, dizziness, headache, asthenia,
lymphadenopathy).
Conclusion: In the context of general medicine in Toledo (Spain), during the 10 months
following the start of the covid-19 vaccination booster, no serious adverse effects were found,
which were mostly symptoms and signs not otherwise specified in middle aged women with
chronic diseases of genitourinary and mental system.
Key Words: COVID-19; Adverse Drug Events; Post-vaccination Reactions; Booster; COVID-19
vaccine; General Practice; Case Series
No comments:
Post a Comment